KR101166342B1 - 아편계 약물 수용체 조절자로서의 신규의 화합물 - Google Patents

아편계 약물 수용체 조절자로서의 신규의 화합물 Download PDF

Info

Publication number
KR101166342B1
KR101166342B1 KR1020067021231A KR20067021231A KR101166342B1 KR 101166342 B1 KR101166342 B1 KR 101166342B1 KR 1020067021231 A KR1020067021231 A KR 1020067021231A KR 20067021231 A KR20067021231 A KR 20067021231A KR 101166342 B1 KR101166342 B1 KR 101166342B1
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
group
phenyl
aminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067021231A
Other languages
English (en)
Korean (ko)
Other versions
KR20060131983A (ko
Inventor
헨리 제이. 브레슬린
차오종 카이
웨이 히
로버트 더블유. 카바쉬
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101166342(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20060131983A publication Critical patent/KR20060131983A/ko
Application granted granted Critical
Publication of KR101166342B1 publication Critical patent/KR101166342B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Amplitude Modulation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067021231A 2004-03-15 2005-03-14 아편계 약물 수용체 조절자로서의 신규의 화합물 Expired - Fee Related KR101166342B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
US60/553,342 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (2)

Publication Number Publication Date
KR20060131983A KR20060131983A (ko) 2006-12-20
KR101166342B1 true KR101166342B1 (ko) 2012-07-18

Family

ID=34962827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067021231A Expired - Fee Related KR101166342B1 (ko) 2004-03-15 2005-03-14 아편계 약물 수용체 조절자로서의 신규의 화합물

Country Status (35)

Country Link
US (8) US7741356B2 (enExample)
EP (5) EP2298744B1 (enExample)
JP (1) JP4778954B2 (enExample)
KR (1) KR101166342B1 (enExample)
CN (2) CN102786476B (enExample)
AR (2) AR048269A1 (enExample)
AT (1) ATE516274T1 (enExample)
AU (1) AU2005224091B2 (enExample)
BR (1) BRPI0508820B8 (enExample)
CA (1) CA2560047C (enExample)
CR (1) CR8655A (enExample)
CY (3) CY1111927T1 (enExample)
DK (5) DK2298744T3 (enExample)
EC (1) ECSP066856A (enExample)
ES (5) ES2367576T3 (enExample)
HR (4) HRP20110694T1 (enExample)
HU (2) HUE029852T2 (enExample)
IL (3) IL178040A (enExample)
LT (2) LT2653465T (enExample)
LU (1) LUC00007I2 (enExample)
ME (3) ME02221B (enExample)
MX (1) MXPA06010642A (enExample)
MY (1) MY146972A (enExample)
NL (1) NL300865I2 (enExample)
NO (3) NO338203B1 (enExample)
NZ (1) NZ549842A (enExample)
PH (1) PH12012501640B1 (enExample)
PL (4) PL2298744T3 (enExample)
PT (4) PT2653465T (enExample)
RS (4) RS51995B (enExample)
SI (4) SI2653465T1 (enExample)
TW (1) TWI361069B (enExample)
UA (1) UA86053C2 (enExample)
WO (1) WO2005090315A1 (enExample)
ZA (1) ZA200608587B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101280929B1 (ko) * 2005-03-14 2013-07-01 얀센 파마슈티카 엔.브이. 오피오이드 모듈레이터의 제조방법

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
LT2653465T (lt) * 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
KR101204751B1 (ko) 2004-05-14 2012-11-27 얀센 파마슈티카 엔.브이. 카복사미도 아편유사약물 화합물
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AR058379A1 (es) * 2005-12-14 2008-01-30 Bristol Myers Squibb Co Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
JP5473334B2 (ja) * 2005-12-23 2014-04-16 ジーランド ファーマ アクティーゼルスカブ 修飾リジン模倣化合物
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
CN101730685A (zh) * 2007-07-09 2010-06-09 詹森药业有限公司 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
HRP20202008T1 (hr) 2013-03-14 2021-02-19 Epizyme, Inc. Inhibitori arginin-metiltransferaze i njihove uporabe
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017007695A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators
EP3325450A1 (en) * 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
JPWO2017043626A1 (ja) * 2015-09-11 2018-06-21 株式会社カネカ 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
EP3463333A4 (en) * 2016-05-30 2019-11-20 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF ELUXADOLINE
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
EP3515434A4 (en) * 2016-09-20 2020-02-26 Sun Pharmaceutical Industries Limited PROCESSES FOR THE PREPARATION OF ELUXADOLINE
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
US20210251964A1 (en) 2018-08-20 2021-08-19 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3659433B1 (de) * 2018-11-30 2021-01-20 Phytobiotics Futterzusatzstoffe GmbH System zur analyse von tierausscheidungsbildern
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
US20230118152A1 (en) 2020-03-30 2023-04-20 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CN116348465A (zh) * 2020-07-28 2023-06-27 爵士制药爱尔兰有限公司 稠合双环raf抑制剂的手性合成
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013658A (en) 1995-01-27 2000-01-11 Novo Nordisk A/S Compounds with growth hormone releasing properties

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
DE69633442T2 (de) 1995-04-13 2006-01-05 Aventis Pharmaceuticals Inc. Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
EP0761220A1 (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues
AR004980A1 (es) 1995-11-29 1999-04-07 Nihon Nohyaku Co Ltd Fungicida para la fruta de cultivo, derivado de fenilalanina comprendido como ingrediente activo en el mismo y metodo para controlar enfermedades enplantas aplicando dicho fungicida.
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
ATE252546T1 (de) * 1999-05-28 2003-11-15 Pfizer Prod Inc 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
CN100400040C (zh) 2000-10-30 2008-07-09 詹森药业有限公司 三肽酶抑制剂
ATE347549T1 (de) * 2001-10-15 2006-12-15 Janssen Pharmaceutica Nv Neue substituierte 4-phenyl-4-(1h-imidazo-2-yl)- piperidin-derivate und ihre anwendung als selective delta-opioid-agonisten
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
LT2653465T (lt) 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
EP1753749B1 (en) * 2004-05-03 2014-07-30 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
BRPI0607792A2 (pt) * 2005-03-14 2009-06-13 Janssen Pharmaceutica Nv processo para a preparação de moduladores de opióides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013658A (en) 1995-01-27 2000-01-11 Novo Nordisk A/S Compounds with growth hormone releasing properties

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101280929B1 (ko) * 2005-03-14 2013-07-01 얀센 파마슈티카 엔.브이. 오피오이드 모듈레이터의 제조방법

Also Published As

Publication number Publication date
EP1725537A1 (en) 2006-11-29
HRP20161331T1 (hr) 2016-12-30
ES2596434T3 (es) 2017-01-09
BRPI0508820B8 (pt) 2022-11-29
NO2017007I2 (no) 2017-02-23
EP2298744B1 (en) 2013-06-26
AR095848A2 (es) 2015-11-18
CA2560047A1 (en) 2005-09-29
ES2705077T3 (es) 2019-03-21
HUS1700010I1 (hu) 2017-03-28
US20140039024A1 (en) 2014-02-06
ES2533176T3 (es) 2015-04-08
IL178040A0 (en) 2006-12-31
US20180325870A1 (en) 2018-11-15
ME02221B (me) 2016-02-20
JP4778954B2 (ja) 2011-09-21
DK1725537T3 (da) 2011-10-31
EP2298744A2 (en) 2011-03-23
EP2573068B1 (en) 2014-12-31
HK1099016A1 (en) 2007-08-03
MXPA06010642A (es) 2007-03-26
US20100324051A1 (en) 2010-12-23
JP2007529527A (ja) 2007-10-25
US10213415B2 (en) 2019-02-26
EP1725537B1 (en) 2011-07-13
US9700542B2 (en) 2017-07-11
ECSP066856A (es) 2006-11-24
AU2005224091A1 (en) 2005-09-29
PT2298744E (pt) 2013-09-12
DK2653465T3 (da) 2016-08-22
EP2573068B9 (en) 2015-08-26
US8772325B2 (en) 2014-07-08
ME02540B (me) 2017-02-20
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
NL300865I2 (nl) 2020-08-17
BRPI0508820A (pt) 2007-08-07
SI2298744T1 (sl) 2013-10-30
US20050203143A1 (en) 2005-09-15
HK1184432A1 (en) 2014-01-24
ATE516274T1 (de) 2011-07-15
ZA200608587B (en) 2008-06-25
DK2298744T3 (da) 2013-09-02
IL229444A0 (en) 2013-12-31
LTPA2017005I1 (lt) 2017-03-27
NL300865I1 (nl) 2017-03-14
AR048269A1 (es) 2006-04-12
PH12012501640A1 (en) 2015-10-05
PL2298744T3 (pl) 2013-11-29
IL178040A (en) 2013-12-31
SI2653465T1 (sl) 2016-10-28
EP3112352B1 (en) 2018-11-21
WO2005090315A1 (en) 2005-09-29
LT2653465T (lt) 2016-09-12
PL2573068T3 (pl) 2015-06-30
ES2367576T3 (es) 2011-11-04
SI1725537T1 (sl) 2011-11-30
EP2653465A1 (en) 2013-10-23
US8344011B2 (en) 2013-01-01
CN102786476B (zh) 2017-01-18
PL2653465T3 (pl) 2017-01-31
KR20060131983A (ko) 2006-12-20
HK1155726A1 (en) 2012-05-25
RS51995B (sr) 2012-04-30
PT2573068E (pt) 2015-04-27
ES2428008T3 (es) 2013-11-05
HRP20150305T1 (hr) 2015-04-24
IL229444A (en) 2017-03-30
PH12012501640B1 (en) 2015-10-05
LUC00007I1 (enExample) 2017-03-03
EP3112352A1 (en) 2017-01-04
CY2017008I1 (el) 2017-11-14
CY2017008I2 (el) 2017-11-14
US20130090478A1 (en) 2013-04-11
CN1950342A (zh) 2007-04-18
EP2573068A1 (en) 2013-03-27
ME01601B (me) 2014-09-20
DK3112352T3 (en) 2019-01-28
TW200539876A (en) 2005-12-16
HUE029852T2 (en) 2017-04-28
HRP20110694T1 (hr) 2011-12-31
NZ549842A (en) 2010-10-29
CR8655A (es) 2008-09-09
US20140256779A1 (en) 2014-09-11
SI2573068T1 (sl) 2015-03-31
DK2573068T3 (en) 2015-02-16
EP2653465B1 (en) 2016-07-13
MY146972A (en) 2012-10-15
NO20064660L (no) 2006-12-14
US7741356B2 (en) 2010-06-22
CN1950342B (zh) 2012-09-26
NO2017007I1 (no) 2017-02-23
LUC00007I2 (enExample) 2017-05-02
NO20160916A1 (no) 2006-12-14
LTC1725537I2 (lt) 2018-02-26
US9205076B2 (en) 2015-12-08
RS52933B (sr) 2014-02-28
RS55122B1 (sr) 2016-12-30
IL224908A (en) 2015-07-30
CY1111927T1 (el) 2015-11-04
PT2653465T (pt) 2016-09-22
UA86053C2 (ru) 2009-03-25
PT1725537E (pt) 2011-09-08
PL1725537T3 (pl) 2011-12-30
RS54199B1 (sr) 2015-12-31
NO338203B1 (no) 2016-08-08
HRP20130800T1 (en) 2013-09-30
AU2005224091B2 (en) 2012-02-02
US7786158B2 (en) 2010-08-31
US8609709B2 (en) 2013-12-17
CA2560047C (en) 2013-12-24
CY1118096T1 (el) 2017-06-28
CN102786476A (zh) 2012-11-21
BRPI0508820B1 (pt) 2018-04-10
US20160030393A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
KR101166342B1 (ko) 아편계 약물 수용체 조절자로서의 신규의 화합물
AU2012202459B2 (en) Novel compounds as opioid receptor modulators
HK1232866B (en) Opioid receptor modulators
HK1155726B (en) Opioid receptor modulators
HK1105967B (en) Novel compounds as opioid receptor modulators
HK1232866A (en) Opioid receptor modulators
HK1099016B (en) Novel compounds as opioid receptor modulators
HK1178896A (en) Compounds as opioid receptor modulators
HK1190391A (en) Opioid receptor modulators
HK1190391B (en) Opioid receptor modulators
HK1178896B (en) Compounds as opioid receptor modulators
AU2013205089A1 (en) Novel compounds as opioid receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150619

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230712

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230712